Biofrontera AG (NASDAQ:BFRA) and Cellectis S.A. (NASDAQ:CLLS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera AG	N/A	0.00	N/A	-0.76	0.00
Cellectis S.A.	25.47M	30.92	82.53M	-2.11	0.00

Table 1 demonstrates Biofrontera AG and Cellectis S.A.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Biofrontera AG (NASDAQ:BFRA) and Cellectis S.A. (NASDAQ:CLLS)’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Biofrontera AG	0.00%	0%	0%
Cellectis S.A.	-324.03%	-23%	-18.8%

Analyst Recommendations

Recommendations and Ratings for Biofrontera AG and Cellectis S.A. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Biofrontera AG	0	0	0	0.00
Cellectis S.A.	0	1	0	2.00

On the other hand, Cellectis S.A.’s potential upside is 34.26% and its consensus target price is $25.

Institutional & Insider Ownership

Institutional investors held 2.04% of Biofrontera AG shares and 29.4% of Cellectis S.A. shares. Insiders held roughly 0.04% of Biofrontera AG’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Biofrontera AG	-4.8%	5.22%	-12.46%	-8.79%	0%	3.25%
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%

For the past year Biofrontera AG was less bullish than Cellectis S.A.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.